ERBB2 and breast carcinoma: A phase III study in patients with early-stage HER2-expressing breast cancer who have finished at least 1 year of post-surgery trastuzumab therapy demonstrated the survival benefit of neratinib versus placebo which led to the approval of U.S. Food and Drug Administration (FDA) in July 2017 [53].